METROPOLIS Metropolis Healthcare Q4 FY26 results (Jan–Mar 2026) and concall
Metropolis Healthcare delivered a strong Q4 and FY26, with MHL Group revenue growing 23.6% to INR 1,646 crores and organic revenue growth of 13.7%, surpassing guidance. The company achieved significant margin expansion, with organic EBITDA margins improving by 140 bps to 25.9% for FY26. Strategic focus on digital engagement, genomics, and operational efficiency, including lab consolidation and network expansion, is driving sustainable growth and profitability.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue up 475.0%, net profit up 75.9% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 11 | 4 | 23 | 23 | 26 +136% | 23 +475% |
| EBITDA | 72 | 62 | 90 | 108 | 95 +32% | 108 +74% |
| Net profit | 31 | 29 | 45 | 53 | 42 +35% | 51 +76% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
